Marchioni, M. Et Al. 2021. Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC).. European urology oncology , vol.4 , 256-263.

Marchioni, M., Kriegmair, M., Heck, M., Amiel, T., Porpiglia, F., Ceccucci, E., ... Campi, R.(2021). Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC).. European urology oncology , vol.4, 256-263.

Marchioni, Michele Et Al. "Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC).," European urology oncology , vol.4, 256-263, 2021

Marchioni, Michele Et Al. "Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC).." European urology oncology , vol.4, pp.256-263, 2021

Marchioni, M. Et Al. (2021) . "Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC).." European urology oncology , vol.4, pp.256-263.

@article{article, author={Michele Marchioni Et Al. }, title={Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC).}, journal={European urology oncology}, year=2021, pages={256-263} }